"Peptide therapy" is searched as though it were one treatment. It is two things that share a name. One is a long-established class of medicines — insulin, the GLP-1 drugs, osteoporosis and cancer treatments — each approved for a stated use on the strength of trials, each with a label. The other is a clinic and wellness menu of compounds such as BPC-157, CJC-1295, ipamorelin and TB-500, most of which were never approved for anything and some of which have never been given to a person in a published study. This page separates the two, places the peptides clinics most often offer into the regulatory position each actually holds on 2026-09-24, and says what that position does and does not mean. It is not advice about any treatment. How brands appear on this site is set out on our disclosure page.
The approved class
Peptides are chains of amino acids — generally shorter than proteins, and the line between a peptide and a protein is a matter of convention rather than chemistry. As medicines they are not new: "more than 80 peptide drugs have reached the market", from insulin onward, for diabetes, cancer, osteoporosis, multiple sclerosis, HIV infection and chronic pain (Muttenthaler et al., Nat Rev Drug Discov 2021). Each of those reached patients through the same route: trials, an application, a label that states what it is for, at what dose and with which warnings.
A few peptides in that class also appear on clinic menus, and in each case the label is narrower than the menu:
| Peptide | US status on 2026-09-24 | What the label covers |
|---|---|---|
| Tesamorelin | Approved: EGRIFTA SV and EGRIFTA WR | Excess abdominal fat in adults with HIV and lipodystrophy; "not indicated for weight loss management" |
| Bremelanotide (PT-141) | Approved: Vyleesi | Acquired low sexual desire in premenopausal women |
| Semaglutide, tirzepatide | Approved: Ozempic, Wegovy, Mounjaro, Zepbound and others | Type 2 diabetes, chronic weight management and further labelled indications |
| Sermorelin | Approved as GEREF, now discontinued | Pediatric growth hormone deficiency and diagnostic use |
| Gonadorelin | Human products discontinued; current labels are veterinary | — |
The tesamorelin label and how it compares with the unapproved ipamorelin is on our tesamorelin vs ipamorelin page; the sermorelin record is on our sermorelin dosage page; the gonadorelin labels are on our gonadorelin dosage page.
How an unapproved peptide reaches a clinic
An unapproved compound can reach a patient in the US through compounding — a pharmacy preparing a drug for an individual prescription — and the rules depend on which kind of compounder is doing it. Section 503A covers state-licensed pharmacies filling individual prescriptions; section 503B covers outsourcing facilities that make larger batches under manufacturing standards. The differences, including why CGMP matters more than anything else between them, are on our 503A vs 503B page.
For a 503A pharmacy, a bulk substance generally has to be a component of an approved drug, have a USP monograph, or appear on the 503A bulks list. While FDA builds that list it sorts nominated substances into categories. The two that matter for peptides:
- Category 2 — significant safety risks. When we read FDA's table on 2026-09-13 it held fourteen substances, five of them peptide-class: GHRP-2, GHRP-6 and ipamorelin acetate under 503B, kisspeptin-10 under 503A, and ibutamoren mesylate under both. FDA's stated grounds for the peptides cluster on immunogenicity — the risk of an immune reaction to an injected peptide — and insufficient safety data. The full table and its dates are on our category 2 page.
- Nominated but withdrawn. Sixteen substances, every one a peptide or peptide-class compound: AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa, emideltide (DSIP), epitalon, GHK-Cu for injection, KPV, pegylated MGF, melanotan II, MOTS-c, selank, semax, thymosin alpha 1 and TB-500. A withdrawn nomination is neither a clearance nor a ban; it means no evaluation produced a listing.
That withdrawn list is, compound for compound, close to what a research supplier sells and a peptide clinic offers.
July 2026: FDA and its advisers disagreed
On July 23–24, 2026 FDA's Pharmacy Compounding Advisory Committee reviewed seven of those withdrawn peptides anyway. FDA's own briefing documents proposed that none be added to the 503A bulks list (FDA briefing document, introduction). The committee voted the other way on six of the seven:
| Peptide | FDA's proposal | Committee vote (as reported) |
|---|---|---|
| BPC-157 | Do not add | For inclusion, 8–6 |
| KPV | Do not add | For inclusion, 8–6 |
| TB-500 | Do not add | For inclusion, 8–6 |
| MOTS-c | Do not add | For inclusion, 7–5, two abstentions |
| Semax | Do not add | For inclusion, 8–5 |
| Epitalon | Do not add | For inclusion, 7–5 |
| Emideltide (DSIP) | Do not add | Against |
Tallies as reported by STAT and PharmExec; when we last checked, fda.gov had posted briefing documents but no minutes or vote record. A committee vote is advice. It does not put a substance on the list, it is not an approval, and it is not a finding that the peptide is safe or works. What FDA's reviewers wrote about the evidence is the more durable record: for MOTS-c, no human exposure data "via any route of administration"; for CJC-1295, reviewed in 2024, 63 healthy adults ever dosed in published studies, 73% of them once. Both reviews are read line by line on our MOTS-c side effects and CJC-1295 side effects pages.
The GLP-1 exception that closed
Semaglutide and tirzepatide are approved drugs, and for a period they were also widely compounded, because they were in shortage — and a drug on FDA's shortage list may be compounded in ways that are otherwise barred. FDA declared the tirzepatide shortage resolved (October 2, 2024, reaffirmed December 19, 2024) and ended its enforcement discretion for compounded tirzepatide on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B facilities; semaglutide followed in April and May 2025. FDA's policy page, current as of 2026-04-01, notes that neither is on the shortage list or the 503B bulks list (FDA). By May 31, 2026 FDA had received more than 730 adverse-event reports associated with compounded tirzepatide and 990 with compounded semaglutide (FDA). Why the approved products are never reconstituted, and where compounded or research powder goes wrong, is on our tirzepatide reconstitution page.
"Research use only" is a third route, not a loophole
Much of what is sold online as peptide therapy is neither an approved drug nor a compounded prescription: it is a vial labelled "for research use only" or "not for human consumption". FDA has warned companies selling semaglutide, tirzepatide and other GLP-1 compounds under that label, and the label does not create a lawful route to a person. What the phrase means, under which regulation, and why it is not a disclaimer that makes a product safe, is on our research-use-only explainer. Whether a given product legally reaches anyone depends on who is selling it and how, which our legal-status page sets out by category.
What sits under "peptide therapy" on a clinic menu
Four questions separate the two meanings of the phrase for any single compound, and every one is checkable in minutes:
- Is there a label? If there is, it states the approved use, dose and warnings; anything else is off-label. Our dosage pages record, compound by compound, whether a label exists.
- Which compounding list is it on? Approved-drug component, 503A bulks list, category 2, or withdrawn — each means something different.
- What human trials exist? A registry count is not a trial count; our dosage and side-effect pages read the records rather than count them.
- What does the adverse-event record hold, and who is obliged to report to it? A small number for an unapproved compound usually means no one is reporting, not that nothing happens — see our peptide side effects page.
What this page does not settle
Whether any peptide is right for any person; whether a particular clinic or pharmacy is operating lawfully; and what FDA will do with its advisers' July votes. The status above is dated and will change. A decision about a specific peptide belongs with a clinician who can see the reader's history.
Sources and dates
Read 2026-09-24: Muttenthaler et al. 2021 (PMID 33536635); FDA briefing documents for the Pharmacy Compounding Advisory Committee meetings of December 4, 2024 (CJC-1295) and July 23–24, 2026 (introduction with FDA's fourteen proposals; MOTS-c evaluation dated 2026-05-11); FDA's GLP-1 compounding policy page (current as of 2026-04-01) and its page on unapproved GLP-1 drugs (current as of 2026-09-01); the EGRIFTA SV label via openFDA (effective 2026-07-29); PharmExec's report of the July 23 vote (2026-07-24). The category 2 and withdrawn lists as read on 2026-09-13 and recorded on our category 2 page; the Vyleesi, GEREF and gonadorelin statuses as recorded on our PT-141, sermorelin and gonadorelin dosage pages; the STAT report of 2026-07-23 and the vote tallies cross-checked against PharmExec and Mintz on 2026-09-21. Corrections go to the contact page.